Case Report: Case studies evaluating anti-HER2 therapy as a tumor-agnostic strategy in rare malignancies
Clinical Scorecard: Case Series: Evaluating the Use of Anti-HER2 Therapy as a Tumor-Agnostic Approach in Uncommon Cancers
At a Glance
| Category | Detail |
|---|
| Condition | Rare tumors with ERBB2 gene amplification |
| Key Mechanisms | HER2-targeted antibody-drug conjugates (ADCs) for treatment |
| Target Population | Patients with ERBB2-amplified rare tumors |
| Care Setting | Oncology, specifically at Bumrungrad International Hospital |
Key Highlights
- Three patients with ERBB2-amplified rare tumors showed meaningful objective responses to ADCs.
- High-level gene amplification can predict ADC efficacy regardless of IHC status.
- Integration of NGS into diagnostic workflows can identify hidden responders.
Guideline-Based Recommendations
Diagnosis
- Utilize next-generation sequencing (NGS) to assess ERBB2 gene amplification.
Management
- Consider trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) for treatment.
Monitoring & Follow-up
- Assess treatment response using RECIST 1.1 criteria.
Risks
- Monitor for treatment-limiting toxicities associated with ADCs.
Patient & Prescribing Data
Patients with rare malignancies exhibiting HER2 expression.
HER2-targeted therapies may extend clinical benefit to subsets of rare cancers.
Clinical Best Practices
- Refine HER2 testing strategies to accurately identify eligible patients.
- Incorporate both IHC and NGS for comprehensive HER2 assessment.
References
